Executive Director - Process Chemistry - Oligonucleotides at Eli Lilly and Company

Indianapolis, Indiana, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Pharmaceuticals, Biotechnology, HealthcareIndustries

Requirements

Extensive knowledge of oligonucleotide development
Fluent knowledge in modern synthetic organic and nucleic acid chemistry methods
Experience in chemistry, manufacturing, and control (CMC) of oligonucleotides
High learning agility with ability to understand and exploit new scientific concepts and methods across multiple disciplines
Strong skills related to automated reactor platforms and purification technologies
Examples of novel contributions to chemical design and mechanism-based problem solving (e.g., total synthesis, novel methodology development, oligonucleotide synthesis), reflected in a strong publication record in peer-reviewed journals
Solid understanding in unit operation design, process modeling, process equipment selection, and scale-up methodologies

Responsibilities

Grow internal capabilities through coaching, mentorship, and leadership
Challenge existing methods, define new manufacturing technologies, and apply them to deliver portfolio and address key CMC challenges
Lead a cross-disciplinary team to evaluate and refine manufacturing routes, technologies, and practices to deliver LGM portfolio
Apply learnings to portfolio of small molecules, oligonucleotides, synthetic peptides, and other emerging synthetic modalities
Build and apply groundbreaking technology and novel platforms within a time-constrained environment
Provide technical leadership in scale-up and demonstration of new chemical processes in development and commercial scale equipment
Collaborate with internal (Lilly Medicine Foundry) and external CMOs on oligonucleotide synthesis, tech transfer, and campaign execution
Lead CMC activities to support clinical trials, product commercialization, and regulatory submissions of oligonucleotide therapeutics
Support development and optimization of methods, exploration of novel synthetic approaches to oligonucleotides and conjugates, plus purification, isolation, and formulation

Skills

Process Chemistry

Oligonucleotides

CMC

Synthetic Chemistry

Drug Substance Development

Drug Product Development

Purification

Formulation

Regulatory Submissions

Clinical Trials

Manufacturing

Genetic Medicines

Eli Lilly and Company

Develops and delivers prescription medicines globally

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company that focuses on discovering, developing, and delivering medicines to improve health. The company has a long history of scientific achievements, including the creation of insulin, the first life-saving treatment for diabetes. Lilly's operations involve extensive research and development to create new medications and enhance existing ones, ensuring they are safe and effective. Their products are primarily prescription medicines sold to healthcare providers for various medical conditions, including diabetes, cancer, and pain management. What sets Lilly apart from its competitors is its strong commitment to ethical practices and the protection of its products from counterfeiting. The company's goal is to enhance lives through innovative medical solutions while maintaining high standards of quality and ethics.

Indianapolis, IndianaHeadquarters

1876Year Founded

$1,180.1MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Risks

Competition from Novo Nordisk's Ozempic may impact tirzepatide's market share.

Potential construction delays in Indiana could affect GLP-1 drug production timelines.

Regulatory challenges may hinder Kisunla's expansion in new Alzheimer's markets.

Differentiation

Eli Lilly's rich history includes the first life-saving insulin treatment.

Lilly's strategic partnerships enhance its position in neurodegenerative disease treatments.

FDA approval of Zepbound opens new therapeutic markets for sleep disorder treatments.

Upsides

Lilly's $9 billion complex in Indiana boosts GLP-1 drug production capacity.

Kisunla's approval in China expands Lilly's Alzheimer's treatment market in Asia.

Collaboration with EVA Pharma enhances Lilly's reputation as socially responsible.

Land your dream remote job 3x faster with AI

Try Jobo Free